Akeso, Inc. (HKG:9926)
124.10
+0.70 (0.57%)
At close: Dec 5, 2025
Akeso Employees
Akeso had 3,035 employees as of December 31, 2024. The number of employees increased by 257 or 9.25% compared to the previous year.
Employees
3,035
Change (1Y)
257
Growth (1Y)
9.25%
Revenue / Employee
779.60K HKD
Profits / Employee
-262.69K HKD
Market Cap
114.31B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 11,000 |
| Hansoh Pharmaceutical Group Company | 8,989 |
| JD Health International | 3,564 |
| Innovent Biologics | 5,659 |
| WuXi Biologics | 12,575 |
| Sino Biopharmaceutical | 24,379 |
| Sichuan Kelun-Biotech Biopharmaceutical | 1,837 |
| Alibaba Health Information Technology | 1,364 |
Akeso News
- 15 days ago - Summit C-Suite Risks Success, Akeso Wins Either Way - Seeking Alpha
- 25 days ago - Akeso, Inc. (AKESF) Presents at 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2025) - Slideshow - Seeking Alpha
- 6 weeks ago - Akeso, Inc. (AKESF) Presents at ESMO Congress 2025 - Slideshow - Seeking Alpha
- 6 weeks ago - China’s Akeso gets share boost as data shows cancer drug’s benefits - South China Morning Post
- 2 months ago - Akeso's Ligufalimab Receives FDA Orphan Drug Designation For Acute Myeloid Leukemia - Nasdaq
- 3 months ago - Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences - Benzinga
- 3 months ago - Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst - Benzinga
- 3 months ago - Akeso (9926.HK) Soars on Positive Lung Cancer Drug Trial Results - GuruFocus